Precigen, Inc. (NASDAQ:PGEN - Get Free Report) shares hit a new 52-week high on Wednesday . The company traded as high as $1.97 and last traded at $1.86, with a volume of 1362520 shares changing hands. The stock had previously closed at $1.70.
Wall Street Analysts Forecast Growth
PGEN has been the subject of a number of research reports. HC Wainwright restated a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. JMP Securities restated a "market outperform" rating and set a $5.00 target price on shares of Precigen in a research report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $7.00.
Get Our Latest Report on Precigen
Precigen Stock Down 1.0 %
The company has a market capitalization of $574.03 million, a price-to-earnings ratio of -3.56 and a beta of 1.66. The business's 50-day moving average is $1.15 and its 200-day moving average is $1.04.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of PGEN. Traphagen Investment Advisors LLC acquired a new stake in Precigen in the 3rd quarter worth about $29,000. Stifel Financial Corp increased its position in shares of Precigen by 94.9% during the third quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 15,680 shares in the last quarter. Envestnet Asset Management Inc. increased its position in shares of Precigen by 29.0% during the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 5,915 shares in the last quarter. Boothbay Fund Management LLC purchased a new stake in shares of Precigen during the fourth quarter worth approximately $35,000. Finally, SG Americas Securities LLC increased its position in shares of Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 13,823 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company's stock.
About Precigen
(
Get Free Report)
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Read More
Before you consider Precigen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precigen wasn't on the list.
While Precigen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
